MedPath
HSA Approval

ORPHENADOL TABLET

SIN07951P

ORPHENADOL TABLET

ORPHENADOL TABLET

December 9, 1994

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Regulatory Information

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Therapeutic

Prescription Only

Formulation Information

TABLET

**Dosage and Administration:** Usual adult dose is 1 tablet twice to four times daily. The dosage should be adjusted according to symptoms and age. To be dispensed on physician’s prescription.

ORAL

Medical Information

**Indication(s):** Indicated as an adjunct to other measures, such as rest and physical therapy, for relief of pain and muscle spasm associated with acute painful musculoskeletal conditions.

**Contraindication(s):** Hypersensitivity to paracetamol, Orphenadrine Citrate and in patients with prostatic enlargement, with paralytic ileus or pyloric stenosis, G-6PD deficiency, anemia, cardiac, pulmonary, renal or hepatic diseases.

N02BE01

paracetamol

Manufacturer Information

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Y S P INDUSTRIES (M) SDN BHD

Active Ingredients

ORPHENADRINE CITRATE

50 mg

Orphenadrine

PARACETAMOL

325 mg

Acetaminophen

Documents

Package Inserts

Orphenadol Tablet PI.pdf

Approved: October 31, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ORPHENADOL TABLET - HSA Approval | MedPath